跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TEVA-BUPRENORPHINE/NALOXONE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
TEVA-BUPRENORPHINE/NALOXONE
Authorized
STANDARD
TEVA-BUPRENORPHINE/NALOXONE
teva canada limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
f91f83685980945c
Company
teva canada limited
Type
Standard
Approval Details
Approval Id
f91f83685980945c
Drug Approval Canada Name
TEVA-BUPRENORPHINE/NALOXONE
Product Name
TEVA-BUPRENORPHINE/NALOXONE
Status
Marketed
Status Date
2021-03-22
Original Market Date
2017-09-28
Din
02453908
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Sublingual
Schedule
Narcotic (CDSA I)
Ahfs
28:10.00
Atc Original
N07BC51 BUPRENORPHINE, COMBINATIONS
Atc Name
n 07 bc 51
Aig Number
0252216001
Company Name
teva canada limited
Company Address
30 Novopharm Court, Toronto, Ontario, Canada, M1B 2K9
Active Ingredients
BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE)
2 MG
NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE)
0.5 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
f91f83685980945c
Type
Standard
Back to Health Canada Approvals